| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
A system to rapidly and accurately evaluate the proportion of HCV mutant strains was developed, which enabled us to further study the efficacy of various direct acting drugs regimens and their relationships with resistant associated variants (RAVs). NS5A-Y93H substitution at baseline could be frequently found and thus regarded as naturally occurring RAV. It was associated with viral titer, the number of mutations within the NS5A-ISDR, ALT levels, and IL28B variant. Association of NS5B-C316N and core 70 amino acid substitutions with human genetic variants were examined and found that there were some associations between viral mutations and human polymorphisms. These findings may provide new insights into an understanding of viral escape from the host immune system and the viral molecular evolution as well as the virological mechanisms of HCV drug resistance.
|
